Tada wrote: "If we we have triplets the company won't be able to answer the volume of calls they will be getting quick enough. How many drugs have had a 30% or greater RRR? How many drugs safely increase eGFR...none? How many drugs have seen patients MoCA scores increase...none? There is zero competition for CKD and cognition drugs that do what apabetalone may do. If we have triplets it's not big news, it's huge news."

Well stated Tada. I agree 100%. It is also important to emphasize that no diabetes drug (SGLT2 inhibitor, GLP-1R agonist, DPP4 inhibitor) or Vascapa on top of standard of care has been proven in clinical trials to reduce MACE in diabetes patients with a recent ACS event. If BETonMACE achieves significant MACE reduction in its patient population, it will be in a league of its own.

Paladin wrote: "To that end the bases are loaded (Cardio, Kidney, Dementia) and now we just need apabetalone to hit a home run."

And a bunch of other apabetalone indications are currently in the minor league right now waiting for that call up to the majors. Plus, there's the IND draft. Which of the thousands of other compounds in the library will be chosen to go from pre-clinical to clinical?

BearDownAZ